HPV positive head and neck cancers: Molecular pathogenesis and evolving treatment strategies

Cancers

Volumn 8, Issue 4, 2016, Pages

  Dok, Rüveyda ^a   Nuyts, Sandra ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Head and neck cancer; HPV; Molecular pathogenesis; Radiation therapy

Indexed keywords

CETUXIMAB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN E6; PROTEIN E7; PROTEIN P21; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; SERINE THREONINE PROTEIN KINASE 1; TRANSCRIPTION FACTOR E2F; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DNA REPAIR; EPIDEMIOLOGICAL DATA; GENE MUTATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; RISK FACTOR; THERAPEUTIC INDEX; THERAPY; THERAPY DEINTENSIFICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS ONCOGENE;

EID: 84962089356     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers8040041     Document Type: Review

References (93)

1. Argiris, A.; Karamouzis, M.V.; Raben, D.; Ferris, R.L. Head and neck cancer. Lancet 2008, 371, 1695-1709. [CrossRef]
2. Leemans, C.R.; Braakhuis, B.J.; Brakenhoff, R.H. The molecular biology of head and neck cancer. Nat. Rev. Cancer 2011, 11, 9-22. [CrossRef] [PubMed]
3. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917. [CrossRef] [PubMed]
4. Rothenberg, S.M.; Ellisen, L.W. The molecular pathogenesis of head and neck squamous cell carcinoma. J. Clin. Investig. 2012, 122, 1951-1957. [CrossRef] [PubMed]
5. Andre, K.; Schraub, S.; Mercier, M.; Bontemps, P. Role of alcohol and tobacco in the aetiology of head and neck cancer: A case-control study in the Doubs region of France. Eur. J. Cancer B Oral Oncol. 1995, 31, 301-309. [CrossRef]
6. Kang, H.; Kiess, A.; Chung, C.H. Emerging biomarkers in head and neck cancer in the era of genomics. Nat. Rev. Clin. Oncol. 2015, 12, 11-26. [CrossRef] [PubMed]
7. Murata, M.; Takayama, K.; Choi, B.C.; Pak, A.W. A nested case-control study on alcohol drinking, tobacco smoking, and cancer. Cancer Detect. Prev. 1996, 20, 557-565. [PubMed]
8. Kutler, D.I.; Auerbach, A.D.; Satagopan, J.; Giampietro, P.F.; Batish, S.D.; Huvos, A.G.; Goberdhan, A.; Shah, J.P.; Singh, B. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch. Otolaryngol. Head Neck Surg. 2003, 129, 106-112. [CrossRef] [PubMed]
9. Chaturvedi, A.K.; Engels, E.A.; Anderson,W.F.; Gillison, M.L. Incidence trends for human papillomavirus-related and-unrelated oral squamous cell carcinomas in the United States. J. Clin. Oncol. 2008, 26, 612-619. [CrossRef] [PubMed]
10. Marur, S.; Forastiere, A.A. Head and neck cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin. Proc. 2008, 83, 489-501. [CrossRef] [PubMed]
11. Sturgis, E.M.; Cinciripini, P.M. Trends in head and neck cancer incidence in relation to smoking prevalence: An emerging epidemic of human papillomavirus-associated cancers? Cancer 2007, 110, 1429-1435. [CrossRef] [PubMed]
12. Agalliu, I.; Gapstur, S.; Chen, Z.; Wang, T.; Anderson, R.L.; Teras, L.; Kreimer, A.R.; Hayes, R.B.; Freedman, N.D.; Burk, R.D. Associations of Oral alpha-, beta-, and gamma-human papillomavirus types with risk of incident head and neck cancer. JAMA Oncol. 2016. [CrossRef] [PubMed]
13. Blitzer, G.C.; Smith, M.A.; Harris, S.L.; Kimple, R.J. Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 2014, 88, 761-770. [CrossRef] [PubMed]
14. Castellsague, X.; Alemany, L.; Quer, M.; Halec, G.; Quiros, B.; Tous, S.; Clavero, O.; Alos, L.; Biegner, T.; Szafarowski, T.; et al. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J. Natl. Cancer Inst. 2016. [CrossRef] [PubMed]
15. Lassen, P.; Primdahl, H.; Johansen, J.; Kristensen, C.A.; Andersen, E.; Andersen, L.J.; Evensen, J.F.; Eriksen, J.G.; Overgaard, J. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer. Radiother. Oncol. 2014, 113, 310-316. [CrossRef] [PubMed]
16. Zhao, N.; Ang, M.K.; Yin, X.Y.; Patel, M.R.; Fritchie, K.; Thorne, L.; Muldrew, K.L.; Hayward, M.C.; Sun, W.; Wilkerson, M.D.; et al. Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancer. Br. J. Cancer 2012, 107, 482-490. [CrossRef] [PubMed]
17. Chung, C.H.; Zhang, Q.; Kong, C.S.; Harris, J.; Fertig, E.J.; Harari, P.M.; Wang, D.; Redmond, K.P.; Shenouda, G.; Trotti, A.; et al. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J. Clin. Oncol. 2014, 32, 3930-3938. [CrossRef] [PubMed]
18. Gillison, M.L.; Castellsague, X.; Chaturvedi, A.; Goodman, M.T.; Snijders, P.; Tommasino, M.; Arbyn, M.; Franceschi, S. Eurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int. J. Cancer 2014, 134, 497-507. [CrossRef] [PubMed]
19. Giuliano, A.R.; Nyitray, A.G.; Kreimer, A.R.; Pierce Campbell, C.M.; Goodman, M.T.; Sudenga, S.L.; Monsonego, J.; Franceschi, S. EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int. J. Cancer 2014, 136, 2752-2760. [CrossRef] [PubMed]
20. Sepiashvili, L.; Bruce, J.P.; Huang, S.H.; O'Sullivan, B.; Liu, F.F.; Kislinger, T. Novel insights into head and neck cancer using next-generation "omic" technologies. Cancer Res. 2015, 75, 480-486. [CrossRef] [PubMed]
21. Giuliano, A.R.; Lee, J.H.; Fulp,W.; Villa, L.L.; Lazcano, E.; Papenfuss, M.R.; Abrahamsen, M.; Salmeron, J.; Anic, G.M.; Rollison, D.E.; et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): A cohort study. Lancet 2011, 377, 932-940. [CrossRef]
22. Satterwhite, C.L.; Torrone, E.; Meites, E.; Dunne, E.F.; Mahajan, R.; Ocfemia, M.C.; Su, J.; Xu, F.; Weinstock, H. Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sex. Transm. Dis. 2013, 40, 187-193. [CrossRef] [PubMed]
23. Kumar, B.; Cordell, K.G.; Lee, J.S.;Worden, F.P.; Prince, M.E.; Tran, H.H.;Wolf, G.T.; Urba, S.G.; Chepeha, D.B.; Teknos, T.N.; et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J. Clin. Oncol. 2008, 26, 3128-3137. [CrossRef] [PubMed]
24. Ang, K.K.; Harris, J.; Wheeler, R.;Weber, R.; Rosenthal, D.I.; Nguyen-Tan, P.F.;Westra,W.H.; Chung, C.H.; Jordan, R.C.; Lu, C.; et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 2010, 363, 24-35. [CrossRef] [PubMed]
25. Fakhry, C.;Westra,W.H.; Li, S.; Cmelak, A.; Ridge, J.A.; Pinto, H.; Forastiere, A.; Gillison, M.L. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 2008, 100, 261-269. [CrossRef] [PubMed]
26. Lassen, P.; Eriksen, J.G.; Hamilton-Dutoit, S.; Tramm, T.; Alsner, J.; Overgaard, J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2009, 27, 1992-1998. [CrossRef] [PubMed]
27. O'Sullivan, B.; Huang, S.H.; Perez-Ordonez, B.; Massey, C.; Siu, L.L.;Weinreb, I.; Hope, A.; Kim, J.; Bayley, A.J.; Cummings, B.; et al. Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother. Oncol. 2012, 103, 49-56. [CrossRef] [PubMed]
28. Chung, C.H.; Gillison, M.L. Human papillomavirus in head and neck cancer: Its role in pathogenesis and clinical implications. Clin. Cancer Res. 2009, 15, 6758-6762. [CrossRef] [PubMed]
29. Doorbar, J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. 2006, 110, 525-541. [CrossRef] [PubMed]
30. Louvanto, K.; Rautava, J.;Willberg, J.;Wideman, L.; Syrjanen, K.; Grenman, S.; Syrjanen, S. Genotype-specific incidence and clearance of human papillomavirus in oral mucosa of women: A six-year follow-up study. PLoS ONE 2013, 8, e53413. [CrossRef] [PubMed]
31. Perez-Ordonez, B.; Beauchemin, M.; Jordan, R.C. Molecular biology of squamous cell carcinoma of the head and neck. J. Clin. Pathol. 2006, 59, 445-453. [CrossRef] [PubMed]
32. Hammerman, P.S.; Hayes, D.N.; Grandis, J.R. Therapeutic insights from genomic studies of head and neck squamous cell carcinomas. Cancer Discov. 2015, 5, 239-244. [CrossRef] [PubMed]
33. Lleras, R.A.; Smith, R.V.; Adrien, L.R.; Schlecht, N.F.; Burk, R.D.; Harris, T.M.; Childs, G.; Prystowsky, M.B.; Belbin, T.J. Unique DNA methylation loci distinguish anatomic site and HPV status in head and neck squamous cell carcinoma. Clin. Cancer Res. 2013, 19, 5444-5455. [CrossRef] [PubMed]
34. Chung, C.H.; Parker, J.S.; Karaca, G.; Wu, J.; Funkhouser, W.K.; Moore, D.; Butterfoss, D.; Xiang, D.; Zanation, A.; Yin, X.; et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004, 5, 489-500. [CrossRef]
35. The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015, 517, 576-582.
36. Robinson, M.; Sloan, P.; Shaw, R. Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol. 2010, 46, 492-496. [CrossRef] [PubMed]
37. Martin, D.; Abba, M.C.; Molinolo, A.A.; Vitale-Cross, L.; Wang, Z.; Zaida, M.; Delic, N.C.; Samuels, Y.; Lyons, J.G.; Gutkind, J.S. The head and neck cancer cell oncogenome: A platform for the development of precision molecular therapies. Oncotarget 2014, 5, 8906-8923. [CrossRef] [PubMed]
38. Suh, Y.; Amelio, I.; Guerrero, U.T.; Tavassoli, M. Clinical update on cancer: Molecular oncology of head and neck cancer. Cell Death Dis. 2014. [CrossRef] [PubMed]
39. Blanchard, P.; Baujat, B.; Holostenco, V.; Bourredjem, A.; Baey, C.; Bourhis, J.; Pignon, J.P. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother. Oncol. 2011, 100, 33-40. [CrossRef] [PubMed]
40. Ang, K.K.; Zhang, Q.; Rosenthal, D.I.; Nguyen-Tan, P.F.; Sherman, E.J.; Weber, R.S.; Galvin, J.M.; Bonner, J.A.; Harris, J.; El-Naggar, A.K.; et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J. Clin. Oncol. 2014, 32, 2940-2950. [CrossRef] [PubMed]
41. Gillison, M.L.; Zhang, Q.; Jordan, R.; Xiao,W.;Westra,W.H.; Trotti, A.; Spencer, S.; Harris, J.; Chung, C.H.; Ang, K.K. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J. Clin. Oncol. 2012, 30, 2102-2111. [CrossRef] [PubMed]
42. Licitra, L.; Perrone, F.; Bossi, P.; Suardi, S.; Mariani, L.; Artusi, R.; Oggionni, M.; Rossini, C.; Cantu, G.; Squadrelli, M.; et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 2006, 24, 5630-5636. [CrossRef] [PubMed]
43. Posner, M.R.; Lorch, J.H.; Goloubeva, O.; Tan, M.; Schumaker, L.M.; Sarlis, N.J.; Haddad, R.I.; Cullen, K.J. Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial. Ann. Oncol. 2011, 22, 1071-1077. [CrossRef] [PubMed]
44. Rischin, D.; Young, R.J.; Fisher, R.; Fox, S.B.; Le, Q.T.; Peters, L.J.; Solomon, B.; Choi, J.; O'Sullivan, B.; Kenny, L.M.; et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J. Clin. Oncol. 2010, 28, 4142-4148. [CrossRef] [PubMed]
45. Psyrri, A.; Rampias, T.; Vermorken, J.B. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. Ann. Oncol. 2014, 25, 2101-2115. [CrossRef] [PubMed]
46. Vermorken, J.B.; Mesia, R.; Rivera, F.; Remenar, E.; Kawecki, A.; Rottey, S.; Erfan, J.; Zabolotnyy, D.; Kienzer, H.R.; Cupissol, D.; et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 2008, 359, 1116-1127. [CrossRef] [PubMed]
47. Vermorken, J.B.; Stohlmacher-Williams, J.; Davidenko, I.; Licitra, L.; Winquist, E.; Villanueva, C.; Foa, P.; Rottey, S.; Skladowski, K.; Tahara, M.; et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label phase 3 randomised trial. Lancet Oncol. 2013, 14, 697-710. [CrossRef]
48. Vermorken, J.B.; Psyrri, A.; Mesia, R.; Peyrade, F.; Beier, F.; de Blas, B.; Celik, I.; Licitra, L. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: Retrospective analysis of the phase III EXTREME trial. Ann. Oncol. 2014, 25, 801-807. [CrossRef] [PubMed]
49. O'Sullivan, B.; Huang, S.H.; Siu, L.L.;Waldron, J.; Zhao, H.; Perez-Ordonez, B.;Weinreb, I.; Kim, J.; Ringash, J.; Bayley, A.; et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J. Clin. Oncol. 2013, 31, 543-550. [CrossRef] [PubMed]
50. Vozenin, M.C.; Lord, H.K.; Hartl, D.; Deutsch, E. Unravelling the biology of human papillomavirus (HPV) related tumours to enhance their radiosensitivity. Cancer Treat. Rev. 2010, 36, 629-636. [CrossRef] [PubMed]
51. Vermeer, D.W.; Spanos, W.C.; Vermeer, P.D.; Bruns, A.M.; Lee, K.M.; Lee, J.H. Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int. J. Cancer 2013, 133, 120-129. [CrossRef] [PubMed]
52. Vu, H.L.; Sikora, A.G.; Fu, S.; Kao, J. HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett. 2010, 288, 149-155. [CrossRef] [PubMed]
53. Spanos, W.C.; Nowicki, P.; Lee, D.W.; Hoover, A.; Hostager, B.; Gupta, A.; Anderson, M.E.; Lee, J.H. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 2009, 135, 1137-1146. [CrossRef] [PubMed]
54. Lassen, P.; Eriksen, J.G.; Hamilton-Dutoit, S.; Tramm, T.; Alsner, J.; Overgaard, J. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother. Oncol. 2010, 94, 30-35. [CrossRef] [PubMed]
55. Kong, C.S.; Narasimhan, B.; Cao, H.; Kwok, S.; Erickson, J.P.; Koong, A.; Pourmand, N.; Le, Q.T. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74, 553-561. [CrossRef] [PubMed]
56. Toustrup, K.; Sorensen, B.S.; Nordsmark, M.; Busk, M.;Wiuf, C.; Alsner, J.; Overgaard, J. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011, 71, 5923-5931. [CrossRef] [PubMed]
57. Toustrup, K.; Sorensen, B.S.; Alsner, J.; Overgaard, J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin. Radiat. Oncol. 2012, 22, 119-127. [CrossRef] [PubMed]
58. Toustrup, K.; Sorensen, B.S.; Lassen, P.; Wiuf, C.; Alsner, J.; Overgaard, J. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother. Oncol. 2012, 102, 122-129. [CrossRef] [PubMed]
59. Hanns, E.; Job, S.; Coliat, P.; Wasylyk, C.; Ramolu, L.; Pencreach, E.; Suarez-Carmona, M.; Herfs, M.; Ledrappier, S.; Macabre, C.; et al. Human Papillomavirus-related tumours of the oropharynx display a lower tumour hypoxia signature. Oral Oncol. 2015, 51, 848-856. [CrossRef] [PubMed]
60. Begg, A.C.; Stewart, F.A.; Vens, C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 2011, 11, 239-253. [CrossRef] [PubMed]
61. Kimple, R.J.; Smith, M.A.; Blitzer, G.C.; Torres, A.D.; Martin, J.A.; Yang, R.Z.; Peet, C.R.; Lorenz, L.D.; Nickel, K.P.; Klingelhutz, A.J.; et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res. 2013, 73, 4791-4800. [CrossRef] [PubMed]
62. Pang, E.; Delic, N.C.; Hong, A.; Zhang, M.; Rose, B.R.; Lyons, J.G. Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6*I. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79, 860-865. [CrossRef] [PubMed]
63. Arenz, A.; Ziemann, F.; Mayer, C.; Wittig, A.; Dreffke, K.; Preising, S.; Wagner, S.; Klussmann, J.P.; Engenhart-Cabillic, R.; Wittekindt, C. Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis. Strahlenther. Onkol. 2014, 190, 839-846. [CrossRef] [PubMed]
64. Gubanova, E.; Brown, B.; Ivanov, S.V.; Helleday, T.; Mills, G.B.; Yarbrough,W.G.; Issaeva, N. Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival. Clin. Cancer Res. 2012, 18, 1257-1267. [CrossRef] [PubMed]
65. Rieckmann, T.; Tribius, S.; Grob, T.J.; Meyer, F.; Busch, C.J.; Petersen, C.; Dikomey, E.; Kriegs, M. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother. Oncol. 2013, 107, 242-246. [CrossRef] [PubMed]
66. Park, J.W.; Nickel, K.P.; Torres, A.D.; Lee, D.; Lambert, P.F.; Kimple, R.J. Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. Radiother. Oncol. 2014, 113, 337-344. [CrossRef] [PubMed]
67. Dok, R.; Kalev, P.; van Limbergen, E.J.; Asbagh, L.A.; Vazquez, I.; Hauben, E.; Sablina, A.; Nuyts, S. p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors. Cancer Res. 2014, 74, 1739-1751. [CrossRef] [PubMed]
68. Lewis, J.S., Jr. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2012, 6, S75-S82. [CrossRef] [PubMed]
69. Lassen, P. The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother. Oncol. 2010, 95, 371-380. [CrossRef] [PubMed]
70. Shah, N.G.; Trivedi, T.I.; Tankshali, R.A.; Goswami, J.V.; Jetly, D.H.; Shukla, S.N.; Shah, P.M.; Verma, R.J. Prognostic significance of molecular markers in oral squamous cell carcinoma: A multivariate analysis. Head Neck 2009, 31, 1544-1556. [CrossRef] [PubMed]
71. Sedghizadeh, P.P.; Billington,W.D.; Paxton, D.; Ebeed, R.; Mahabady, S.; Clark, G.T.; Enciso, R. Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis. Oral Oncol. 2016, 54, 15-27. [CrossRef] [PubMed]
72. Lewis, J.S., Jr.; Thorstad,W.L.; Chernock, R.D.; Haughey, B.H.; Yip, J.H.; Zhang, Q.; El-Mofty, S.K. p16 positive oropharyngeal squamous cell carcinoma: An entity with a favorable prognosis regardless of tumor HPV status. Am. J. Surg. Pathol. 2010, 34, 1088-1096. [CrossRef] [PubMed]
73. Perrone, F.; Gloghini, A.; Cortelazzi, B.; Bossi, P.; Licitra, L.; Pilotti, S. Isolating p16-positive/HPV-negative oropharyngeal cancer: An effort worth making. Am. J. Surg. Pathol. 2011, 35, 774-777. [CrossRef] [PubMed]
74. Richards, L. Genetics: Staging and prognostic value of p16 expression in oropharyngeal cancer. Nat. Rev. Clin. Oncol. 2010. [CrossRef] [PubMed]
75. Rietbergen, M.M.; Brakenhoff, R.H.; Bloemena, E.; Witte, B.I.; Snijders, P.J.; Heideman, D.A.; Boon, D.; Koljenovic, S.; Baatenburg-de Jong, R.J.; Leemans, C.R. Human papillomavirus detection and comorbidity: Critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. Ann. Oncol. 2013, 24, 2740-2745. [CrossRef] [PubMed]
76. Nuyts, S.; Dirix, P.; Clement, P.M.; Poorten, V.V.; Delaere, P.; Schoenaers, J.; Hermans, R.; van den Bogaert, W. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73, 1088-1095. [CrossRef] [PubMed]
77. Pignon, J.P.; le Maître, A.; Maillard, E.; Bourhis, J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 2009, 92, 4-14. [CrossRef] [PubMed]
78. Bentzen, S.M. Radiobiological considerations in the design of clinical trials. Radiother. Oncol. 1994, 32, 1-11. [CrossRef]
79. Masterson, L.; Moualed, D.; Liu, Z.W.; Howard, J.E.; Dwivedi, R.C.; Tysome, J.R.; Benson, R.; Sterling, J.C.; Sudhoff, H.; Jani, P.; et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: A systematic review and meta-analysis of current clinical trials. Eur. J. Cancer 2014, 50, 2636-2648. [CrossRef] [PubMed]
80. Kimple, R.J.; Harari, P.M. Is radiation dose reduction the right answer for HPV-positive head and neck cancer? Oral Oncol. 2014, 50, 560-564. [CrossRef] [PubMed]
81. Psyrri, A.; Seiwert, T.Y.; Jimeno, A. Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am. Soc. Clin. Oncol. Educ. Book 2013, 246-255. [CrossRef] [PubMed]
82. Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354, 567-578. [CrossRef] [PubMed]
83. Agrawal, N.; Frederick, M.J.; Pickering, C.R.; Bettegowda, C.; Chang, K.; Li, R.J.; Fakhry, C.; Xie, T.X.; Zhang, J.; Wang, J.; et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333, 1154-1157. [CrossRef] [PubMed]
84. Stransky, N.; Egloff, A.M.; Tward, A.D.; Kostic, A.D.; Cibulskis, K.; Sivachenko, A.; Kryukov, G.V.; Lawrence, M.S.; Sougnez, C.; McKenna, A.; et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333, 1157-1160. [CrossRef] [PubMed]
85. Bonner, J.A.; Harari, P.M.; Giralt, J.; Cohen, R.B.; Jones, C.U.; Sur, R.K.; Raben, D.; Baselga, J.; Spencer, S.A.; Zhu, J.; et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010, 11, 21-28. [CrossRef]
86. Rosenthal, D.I.; Harari, P.M.; Giralt, J.; Bell, D.; Raben, D.; Liu, J.; Schulten, J.; Ang, K.K.; Bonner, J.A. Association of human papillomavirus and p16 status with outcomes in the IMCL-9815 phase III registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetuximab. J. Clin. Oncol. 2015. [CrossRef]
87. Abazeed, M.E.; Adams, D.J.; Hurov, K.E.; Tamayo, P.; Creighton, C.J.; Sonkin, D.; Giacomelli, A.O.; Du, C.; Fries, D.F.;Wong, K.K.; et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013, 73, 6289-6298. [CrossRef] [PubMed]
88. Lui, V.W.; Hedberg, M.L.; Li, H.; Vangara, B.S.; Pendleton, K.; Zeng, Y.; Lu, Y.; Zhang, Q.; Du, Y.; Gilbert, B.R.; et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 2013, 3, 761-769. [CrossRef] [PubMed]
89. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8, 193-204. [CrossRef] [PubMed]
90. Sanchez-Perez, I. DNA repair inhibitors in cancer treatment. Clin. Transl. Oncol. 2006, 8, 642-646. [CrossRef] [PubMed]
91. Shaheen, M.; Allen, C.; Nickoloff, J.A.; Hromas, R. Synthetic lethality: Exploiting the addiction of cancer to DNA repair. Blood 2011, 117, 6074-6082. [CrossRef] [PubMed]
92. Maxmen, A. Beyond PARP inhibitors: Agents in pipelines target DNA repair mechanisms. J. Natl. Cancer Inst. 2010, 102, 1110-1111. [CrossRef] [PubMed]
93. Chalmers, A.J.; Lakshman, M.; Chan, N.; Bristow, R.G. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin. Radiat. Oncol. 2010, 20, 274-281. [CrossRef] [PubMed]